Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Abstract of this article Free
space
 arrow  Figures/Tables List
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Maron, B. J.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

UPDATE

Cardiovascular Risks to Young Persons on the Athletic Field

right arrow Barry J. Maron, MD

1 September 1998 | Volume 129 Issue 5 | Pages 379-386

Sudden cardiac deaths of young athletes, which are usually associated with physical exertion, continue to achieve high public visibility and generate considerable concern.Despite broad community participation in sports, such catastrophes are uncommon, occurring in about 1/200 000 high school athletes per academic year. Various unsuspected congenital cardiovascular diseases are usually responsible; the most common lesions are hypertrophic cardiomyopathy and several congenital coronary artery anomalies. Selected reports suggest that arrhythmogenic right ventricular dysplasia may be a more common cause of these deaths than previously suspected. In some trained athletes with borderline increases in thickness of the left ventricular wall, mild morphologic expression of hypertrophic cardiomyopathy can often be distinguished from the physiologic consequences of athlete's heart by noninvasive clinical assessment and testing. In addition, the recognized cardiovascular risks of the athletic field are now extended to include cardiac arrest resulting from relatively modest, nonpenetrating chest blows produced by projectiles (such as baseballs) or bodily contact in the absence of underlying cardiac disease and without structural injury to the chest wall or heart. These uncommon but usually fatal events seem to result when chest impact occurs precisely during the vulnerable phase of repolarization, and they may be reduced by use of softer baseballs.

Preparticipation screening for cardiovascular disease, consisting of standard history and physical examination, is customary practice for most high school and college athletes in the United States.Evidence suggests, however, that the present screening process for cardiovascular disease in high school athletes may be largely inadequate, given the content of the approved screening questionnaires (which serve as guidelines for the process) and the use of examiners with little cardiovascular training. This emphasizes the need for national standardization of preparticipation screening. The recommendations of the 26th Bethesda Conference for disqualification from competitive athletics are now a standard for management decisions when cardiovascular abnormalities are identified in trained athletes.


The past several years have seen increasing interest and concern in the medical and lay communities about sudden and unexpected catastrophes in young trained athletes [1]. The risks associated with participation in organized competitive sports are diverse, ranging from sudden collapse due to various underlying (and usually unsuspected) cardiovascular diseases [2-12] to deaths from nonpenetrating chest impact [13-15].

It should be emphasized that although these events are devastating, they seem to be uncommon relative to the vast numbers of young athletes participating safely in a wide range of sporting activities [3, 16]. Therefore, information about deaths on the athletic field should not raise undue anxiety and inhibit sports participation. On the other hand, the sudden death of young athletes remains an important medical and societal issue, and uncertainty about the level of risk incurred by apparently healthy young persons participating in sports is a persistent source of concern and anxiety for athletes and their parents, families, coaches, and health care providers. Indeed, the medical profession has a responsibility to create a better-informed public; to pursue, when practical, early detection of diseases or conditions that may cause catastrophic events in young athletes; and to design potentially effective preventive measures.

Although the news media have somewhat sensationalized these tragedies by routinely making the deaths of young athletes widely publicized news events, this very process has also been instrumental in permitting the assembly of data that have defined the causes of these deaths [2, 3]. In this Update (which excludes considerations related to middle-aged athletes and the many benefits of exercise for the general population), I attempt to place into perspective the cardiovascular-related risks associated with organized sports competition and initiatives that may create a safer sports environment for young athletes.


Risks Associated with Unsuspected Cardiovascular Disease
space

Prevalence and Significance

Although sudden and unexpected cardiovascular deaths occurring in young athletes during organized competitive sports are generally acknowledged to be uncommon, the precise frequency of these deaths is unknown. Many practical obstacles impede the assembly of such data. Although reasonable estimates of the numbers of high school and college athletes are available, systematic tracking of sudden deaths is challenging without a national registry. Consequently, estimates of the prevalence of sudden death that rely on reporting from individual schools and institutions and on news media accounts [2, 3] probably underestimate the occurrence of these events in the United States. The best available estimates, based on national or state populations, suggest that despite the broad participation in organized sports, sudden death from cardiovascular disease in high school or college athletes is rare, occurring in about 1/200 000 [16] to 1/300 000 [3] individual student-athletes per academic year and in about 1/70 000 individual student-athletes over a 3-year high school career [16]. In comparison, higher rates of sudden death related to exercise have been reported for apparently healthy male athletes [17], joggers [18], and marathon racers [19] (about 1/15 000 to 1/50 000 per year).

The infrequent occurrence of deaths on the athletic field suggests that the intense and persistent public interest in these rare but particularly devastating events may be disproportionate to their overall significance in the general population. Indeed, these deaths occur much less commonly in the first three decades of life than other public health problems, such as accidents, homicides, and the consequences of illicit drug use. Nevertheless, the emotional, medical, and societal impact of sudden cardiovascular death in young persons remains high. To much of the public and the medical community, the young competitive athlete is the healthiest member of society. The unexpected collapse of such persons during organized sports activities, which are widely considered safe, inevitably strikes to the core of our personal sensibilities [1].

Causes of Sudden Death

Several reports have documented the causes of nontraumatic sudden death in young persons participating in athletic activities (including organized competitive sports) [1-12]. Such studies incriminate a diverse pathologic substrate of about 20 predominantly congenital cardiovascular conditions; these structural abnormalities are unrelated to the physiologic cardiac adaptations normally associated with systematic athletic training (athlete's heart) [20-23]. Indeed, any disease that can cause sudden death in a young person may also be responsible for such an event in a trained athlete. These cardiovascular lesions usually provide few or no premonitory signs and symptoms and are unlikely to be diagnosed during life [2-9].

The frequency with which particular diseases cause death in competitive athletes varies considerably. Most lesions are responsible for 5% or less of the total; these lesions include ruptured aortic aneurysm (usually in the context of the Marfan syndrome), idiopathic dilated cardiomyopathy, aortic valve stenosis, the long QT syndrome, and myocarditis [2]. The occurrence of myocarditis in this population may be underestimated because of the unique difficulties implicit in validating the clinical and autopsy diagnosis [24-27]. Although myocarditis is usually viral in origin, long-term drug abuse (such as with cocaine) may produce profound and deleterious cardiovascular consequences or death through various mechanisms and morphologic changes that can mimic viral myocarditis, including myocardial ischemia, inflammation, and fibrosis [28-30]. Atherosclerotic coronary artery disease has been cited in numerous reports as an uncommon cause of sudden death in young athletes [2, 3, 5, 6], but some authors have reported higher frequencies of obstructive atherosclerosis, often in the context of single-vessel disease without acute thrombosis [4, 31].

In most published surveys, the single most common cardiovascular lesion causing sudden death in young athletes (about one third of cases) is hypertrophic cardiomyopathy [2, 3, 5, 6, 8]. Hypertrophic cardiomyopathy is a primary and familial cardiac disease with heterogeneous expression for which more than 100 disease-causing mutations in five genes encoding proteins of the sarcomere have been reported [32-39]. The condition is now viewed as more common than previously believed and is identifiable by echocardiography in about 0.2% (1 in 500) of the general population [40]. The association of hypertrophic cardiomyopathy with the risk for sudden and unexpected cardiac death (often during exertion) has been emphasized repeatedly [32-3537, 41-44]. However, the ability to accurately stratify risk for sudden death in any individual athlete with hypertrophic cardiomyopathy is limited by the clinical and pathophysiologic heterogeneity of this disorder and the many mechanisms believed to be responsible for cardiovascular collapse [35, 37, 42].

On the basis of analysis of tertiary referral populations, sudden death in hypertrophic cardiomyopathy seems to have a predilection for young, asymptomatic persons and frequently occurs during moderate or severe exertion [41]. Of note, this clinical profile is consistent with that of young athletes who die suddenly of hypertrophic cardiomyopathy [2]. Indeed, with a disease such as hypertrophic cardiomyopathy, which has the propensity for potentially fatal arrhythmias [43-45], the stress of intense athletic training and competition (as well as associated alterations in blood volume, hydration, and electrolytes) undoubtedly compounds the risk for a sudden cardiac event associated with exertion.

Young athletes who have died suddenly sometimes have nondilated hearts with only modest increases in left ventricular mass (and wall thickness) at autopsy for which the morphologic findings cannot support a definitive diagnosis of hypertrophic cardiomyopathy [2]. An unresolved issue is whether such athletes have a mild morphologic expression of hypertrophic cardiomyopathy [2, 22, 32, 35]; it can also be speculated that athlete's heart [20-23] with substantial degrees of physiologic hypertrophy may have catastrophic consequences under unique circumstances.

The second most common category of diseases responsible for sudden death in young athletes is a spectrum of congenital malformations of the coronary arteries; the most important of these is anomalous origin of the left main coronary artery from the right (anterior) sinus of Valsalva [2-68, 47, 48]. These coronary anomalies are particularly uncommon and are usually identified only at autopsy. Indeed, clinical recognition requires a high index of suspicion. Although definitive clinical diagnosis necessitates coronary arteriography, transthoracic and transesophageal echocardiography [49-51] may strongly suggest (or even identify) such lesions in selected patients.

According to most reports [2-6], arrhythmogenic right ventricular dysplasia is an uncommon cause of sudden death; of note, however, this disease has emerged as the predominant lesion in young trained athletes dying suddenly within the Veneto region of northeastern Italy [7, 9, 52]. The relatively frequent occurrence of arrhythmogenic right ventricular dysplasia as a cause of premature death in this geographic area may reflect a unique genetic substrate. Alternatively, the long-standing Italian national program for the systematic cardiovascular assessment of competitive athletes may have disqualified disproportionate numbers of trained athletes with hypertrophic cardiomyopathy [53]. As a consequence, arrhythmogenic right ventricular dysplasia (which is particularly difficult to detect clinically) may have achieved greater exposure in the athletic population, including the high-risk subset that eventually died. Furthermore, hypertrophic cardiomyopathy may convey a relatively low risk for sudden death in Italy (as recent studies from the northwestern and central regions of that country suggest) [45, 54, 55], thereby accounting for its rarity as a cause of athletic field deaths.

Demographic Characteristics

Most (about 90%) sudden cardiac deaths caused by hypertrophic cardiomyopathy and other lesions reported in athletes have occurred in association with exercise, predominantly in the late afternoon and early evening; this corresponds to the peak periods of competition and practice in organized team sports, such as football and basketball [2]. Of note, this demographic pattern of sudden death in athletes contrasts strikingly with previous observations in patients with hypertrophic cardiomyopathy (who were not involved in athletic activities) for whom a prominent early to mid-morning peak for sudden death was evident, similar to that reported in patients with acute myocardial infarction or angina [56]. Taken together, these observations suggest that in the presence of certain structural cardiovascular diseases, intense physical exertion represents a trigger and important precipitating factor for sudden collapse on the athletic field [2]. These findings also support consensus recommendations that it is both prudent and justifiable to remove athletes with particular cardiac diseases from intense sporting activities to diminish their perceived risk for catastrophic events [57].

Deaths on the athletic field show a striking difference between the sexes: Only about 10% of these deaths occur in female athletes [2, 3]. This difference may exist because women 1) participate less commonly in high school and college sports programs than men (by a 2:1 ratio) [3], 2) are often exposed to generally less intensive training demands than men, 3) do not participate in sports [such as football] that are associated with the greatest risk for sudden death, and 4) less commonly have certain cardiovascular lesions responsible for sudden death (in particular, hypertrophic cardiomyopathy) [32-35].

Race also seems to play a role in deaths on the athletic field; evidence suggests that hypertrophic cardiomyopathy is an important cause of sudden death in young African-American male athletes [2, 4, 58]. This observation is of interest because it contrasts sharply with the infrequent reporting of black patients with hypertrophic cardiomyopathy in hospital-based tertiary center populations [58]. Therefore, hypertrophic cardiomyopathy is usually encountered in young African Americans when it results in sudden and unexpected death during competitive sports. These data emphasize the disproportionate access to subspecialty medical care and sophisticated cardiovascular diagnosis in the African-American and white communities in the United States. Therefore, it is less likely that young black males will be identified with hypertrophic cardiomyopathy and consequently disqualified from competition to reduce their risk for sudden death (in accordance with the recommendations of the 26th Bethesda Conference, discussed later in this paper) [57].

Mechanisms and Resuscitation

The precise mechanism ultimately responsible for sudden death in young athletes depends on the disease state involved. In most cases, however, including athletes with hypertrophic cardiomyopathy, death probably results from electrical instability and ventricular tachyarrhythmias. Rarely is an athlete with cardiovascular disease successfully resuscitated after cardiac arrest on the athletic field.

It has been suggested that widespread availability of automatic external defibrillators designed for public access would result in the survival of many athletes experiencing cardiac arrest [59]. Although some benefits undoubtedly ensue from this strategy, the great infrequency with which these events occur would itself represent an important obstacle to efficient resuscitation practice [2, 3].

Differential Diagnosis of Cardiac Disease and Athlete's Heart

In some trained athletes with left ventricular hypertrophy, it may be difficult to distinguish physiologic cardiac adaptations to athletic training (that is, athlete's heart) from pathologic conditions [60]. This differential diagnosis may involve athletes with borderline increased thickness of the left ventricular wall (the "gray zone"; thickness of 13 to 15 mm), creating confusion between the extreme morphologic consequences of training and hypertrophic cardiomyopathy; such distinctions are often resolvable with clinical assessment and echocardiography [60]. The substantial genetic heterogeneity in hypertrophic cardiomyopathy and the expensive, time-intensive techniques of genotyping do not yet permit laboratory-based DNA diagnosis to be routinely available in this clinical setting [61]. In other athletes, a left ventricular cavity that is particularly enlarged (≥ 60 mm) may suggest dilated cardiomyopathy (Pelliccia A, Culasso F, Di Paolo F, Caselli G, Maron BJ. Physiologic left ventricular cavity dilatation in elite athletes. Submitted for publication).

The clinical distinction between athlete's heart and cardiac disease has important implications for trained athletes because identification of cardiovascular disease may be the basis for disqualification from competition in an effort to minimize risk [57, 62]. By the same token, the improper diagnosis of cardiac disease in an athlete may lead to unnecessary withdrawal from athletics, depriving that person of the benefits of sports.


Preparticipation Screening and Detection of Cardiovascular Abnormalities
space

Detection of preexisting cardiovascular abnormalities with the potential for substantial morbidity or sudden death is an important objective of preparticipation screening currently in place in U.S. high schools and colleges [63]. Large-scale athletic screening has traditionally been performed in the context of a history (personal and family) and physical examination. However, the practicality and utility of the screening process are limited by the uncommon occurrence of these relevant cardiovascular lesions in the general population and the large size of the competitive athletic population (perhaps 8 to 10 million persons every year). Indeed, one retrospective study showed that cardiovascular abnormalities were suspected by history and physical examination screening in only 3% of the high school and college athletes who ultimately died suddenly of cardiac disease [2]. Of note, prospective studies in large athletic populations using echocardiography and electrocardiography have also shown a low yield of identifiable cardiovascular disease [64-66].

Nevertheless, an American Heart Association consensus panel [63] recently supported the principle of preparticipation cardiovascular screening for young competitive athletes on both medical and ethical grounds. The panel recommended a history (personal and family) and physical examination targeted to the cardiovascular lesions known to be responsible for sudden death or disease progression; although this method is imperfect, the panel nonetheless considered it the most practical and best available strategy for screening large populations of young athletes. In addition, the panel offered specific recommendations on the composition of the history and physical examination (Table 1) and the selection of examiners.


View this table:
[in this window]
[in a new window]
 
Table 1. American Heart Association Consensus Panel Recommendations for Preparticipation Screening of Young Athletes

 

In its current form, the preparticipation screening process for high school athletes seems to be substantially flawed. A major impediment lies in the design of the approved history and physical examination forms that represent guidelines to the examiners in 43 U.S. states (including the District of Columbia) (the other 8 states have no such questionnaires) [67]. Indeed, 40% of the states either have no formal screening requirement or approved history and physical examination questionnaires or have forms that were judged inadequate when measured against the American Heart Association 1996 consensus panel screening guidelines [63]. Therefore, there is a crucial need to consider ways for standardizing the preparticipation history and physical examination on a national basis (as well as requirements for the expertise and training of the designated examiners) so that they conform more closely to the specific American Heart Association recommendations [63]. Indeed, preparticipation sports examinations are performed by a wide variety of health care workers with vastly different levels of training and expertise in the diagnosis of cardiovascular disease. All states that have a specific policy sanction physicians to perform preparticipation examinations. In addition, 21 states also permit nurses or physician assistants to administer examinations, and 11 states specifically provide for practitioners with limited cardiovascular training (such as chiropractors and naturopathic clinicians). An improved screening process will undoubtedly result in the detection of more athletes with important lesions and ultimately, by virtue of treatment or disqualification from intense sports, will diminish the overall risk for sudden death.

The addition of noninvasive testing (such as echocardiography or electrocardiography) to preparticipation screening would enhance the identification of many abnormalities, particularly hypertrophic cardiomyopathy [63]. The American Heart Association panel [63], although not specifically discouraging individual initiatives for large-scale screening that incorporates testing, concluded that consistent implementation of such strategies on a national scale in the United States was impractical and prohibitive because of the considerable size of the athlete population, cost-efficacy considerations, and such issues as anxiety (and the possibility of unjustified disqualification) created by false-positive and borderline test results. The largest screening effort for the detection of cardiovascular abnormalities in athletic populations, routinely involving electrocardiography, has been ongoing in Italy since 1982 as part of a national evaluation program for competitive athletes [53, 68]. It is unlikely that such a program will ever be implemented in the United States, given the much larger population (five times that of Italy) and other practical considerations, including obstacles to funding.

It should be emphasized, however, that no large-scale screening effort (even with noninvasive testing) can detect all important lesions in affected athletes [63]. Consequently, medical clearance for sports should not promulgate a false sense of security or an unrealistic expectation that the athlete is free of potentially fatal cardiovascular disease. Indeed, physicians and other health care providers who perform preparticipation evaluations probably bear a responsibility to inform athletes and their families of the limitations inherent in screening for cardiovascular disease, as well as the small risks that may remain for athletes even after normal findings on a screening examination.

Preparticipation examinations in the United States occur largely at the discretion of the examining physician as customary practice, based on requirements of high schools and colleges. A considerably different circumstance has existed in Italy since 1971 in the form of benevolent government legislation (the Medical Protection of Athletic Activities Act) that mandates preventive medical evaluations for all competitive athletes [53]. In this unique program, supported financially by the government, all citizens 12 to 35 years of age who wish to engage in organized sports activities must achieve annual medical clearance from an approved physician stipulating that they have no abnormalities that could unacceptably increase the risk for sudden death during training or competition. Since 1982, more detailed guidelines for these preparticipation examinations have been formulated to include history and physical examination, 12-lead electrocardiography, and exercise and pulmonary function tests. Since 1994, echocardiography has been specifically required only in selected professional sports (soccer, boxing, and cycling). Under Italian law, the examining physician is primarily responsible for the accuracy of this clinical assessment and stands as the final judge of eligibility for sports by issuing an official certification of medical clearance. In the event of an incorrect medical diagnosis that leads directly to the impaired health or the death of an athlete, the physician who sanctioned athletic competition can be held accountable in criminal and civil court.


Eligibility Considerations for Athletes Known To Have Cardiovascular Disease
space

When a significant cardiovascular abnormality is identified in a competitive athlete, certain considerations arise with respect to the magnitude of risk for sudden cardiac death with continued participation in organized sports and the appropriate criteria with which to determine whether a given athlete will probably benefit from disqualification. In this regard, the 26th Bethesda Conference, sponsored by the American College of Cardiology, offers specific and prospective consensus panel recommendations [57] for athletic eligibility. This reference document considers the nature and severity of approximately 70 relevant cardiovascular abnormalities and diseases, the character of the sports training and competition, and available information on risk stratification for cardiac events. The recommendations of the 26th Bethesda Conference [57] are predicated on the likelihood that intense athletic training and competition increase the risk for sudden cardiac death or disease progression in athletes with certain structural heart diseases [2]. Although it is not yet possible to precisely predict or quantify that risk, it is a prudent presumption that the temporary or permanent withdrawal of selected athletes from intense competitive sports mitigates the perceived risk. These considerations are particularly relevant to a heterogeneous disease such as hypertrophic cardiomyopathy, in which risk stratification remains imprecise [35, 37, 42].

The fact that it is difficult to stratify risk among individual athletes with hypertrophic cardiomyopathy is reflected in the recommendations of the 26th Bethesda Conference [57] for athletic eligibility. These guidelines are conservative and homogeneous for young athletes with an unequivocal diagnosis of hypertrophic cardiomyopathy. The recommendations advise that such athletes withdraw from intense competitive sports.

Both the 26th Bethesda Conference report (1994) [57] and the American Heart Association screening recommendations (1996) [63] provide clear benchmarks for the expected standards of care that may be used to resolve medicolegal disputes in individual cases. Indeed, the 26th Bethesda Conference was recently cited by a U.S. Court of Appeals as consensus medical guidelines that the team physician should rely on in appropriately formulating decisions on the disqualification of competitive athletes with cardiovascular disease [69].


Cardiac Risks on the Athletic Field Unrelated to Underlying Cardiovascular Disease
space

Although sudden death in young athletes due largely to congenital heart diseases [2-12] has achieved great visibility, other unusual risks of organized or recreational sports activity leading to cardiovascular collapse have recently been emphasized. For example, although uncommon, virtually instantaneous cardiac arrest may result from a relatively modest and nonpenetrating blow to the chest-in the absence of underlying cardiovascular disease [13, 14, 70] or structural injury to the chest wall or heart itself.

In such occurrences, which have been called commotio cordis ("disturbed or agitated heart motion") [71], blunt chest impact over the anatomic position of the heart is usually produced by a projectile (most commonly a baseball) or by bodily collision with another athlete. The chest blow is not perceived as unusual for the sporting event or necessarily of sufficient magnitude to result in a catastrophe. The most common scenario during competitive sports is that of a young baseball player struck in the chest, while batting, by a pitched ball thrown from a standard distance. Of note, many of these catastrophes have occurred in purely recreational situations at home or on the playground, with the fatal injuries often produced by family members. Although the precise mechanisms responsible for the cardiac arrest are not known with certainty, a recently developed experimental model in swine closely simulates the clinical profile of commotio cordis and provides important insights [72]. The model shows that a precordial blow can create devastating electrophysiologic consequences, largely by virtue of its precise timing. When chest impact occurred with modest force (30 miles per hour) during a narrow window of 15 to 30 ms before the T-wave peak, thereby interfering with the vulnerable phase of repolarization, ventricular fibrillation occurred instantaneously and reproducibly [72].

Furthermore, softer-than-standard safety baseballs reduced the risk for ventricular fibrillation, suggesting that sudden death from commotio cordis during certain youth sporting activities may be prevented by modifying athletic equipment [72]. However, the low event rate for commotio cordis creates an obstacle to documenting the effectiveness of any protective intervention. In addition, about 15% of reported victims of commotio cordis were equipped with protective padding over some portion of the anterior chest wall at the time of their injury and collapse [70]. Indeed, it is probably impossible to achieve absolute protection and "zero risk" from all adverse eventualities of sports participation while at the same time preserving the integrity of competition.

Commotio cordis events are not uniformly fatal, and about 10% of reported victims are known to have survived, usually because of reasonably prompt cardiopulmonary resuscitation and defibrillation [14, 70]. With enhanced public awareness of this syndrome, emergency measures are more likely to be promptly implemented on the athletic field, possibly avoiding many future catastrophes. Nonpenetrating chest blows (particularly when delivered by a soccer ball at high velocity) can also produce nonfatal, acute myocardial infarction in otherwise normal athletes [73]. Although the mechanism by which these events occur is uncertain, myocardial ischemia and infarction may result from direct compression of a coronary artery that produces spasm or possibly coronary thrombosis.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

From Minneapolis Heart Institute Foundation, Minneapolis, Minnesota. For current author addresses, see end of text.
Requests for Reprints: Barry J. Maron, MD, Minneapolis Heart Institute Foundation, 920 East 28th Street, Suite 40, Minneapolis, MN 55407.


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Maron BJ. Sudden death in young athletes. Lessons from the Hank Gathers affair. N Engl J Med. 1993; 329:55-7.

2. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathologic profiles. JAMA. 1996; 276:199-204.

3. Van Camp SP, Bloor CM, Mueller FO, Cantu RC, Olson HG. Nontraumatic sports death in high school and college athletes. Med Sci Sports Exerc. 1995; 27:641-7.[Medline]

4. Burke AP, Farb A, Virmani R, Goodin J, Smialek JE. Sports-related and non-sports-related sudden cardiac death in young adults. Am Heart J. 1991; 121:568-75.

5. Maron BJ, Roberts WC, McAllister HA, Rosing DR, Epstein SE. Sudden death in young athletes. Circulation. 1980; 62:218-29.

6. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol. 1986; 7:204-14.

7. Corrado D, Thiene G, Nava A, Rossi L, Pennelli N. Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases. Am J Med. 1990; 89:588-96.

8. Liberthson RR. Sudden death from cardiac causes in children and young adults. N Engl J Med. 1996; 334:1039-44.

9. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988; 318:129-33.

10. Thiene G, Pennelli N, Rossi L. Cardiac conduction system abnormalities as a possible cause of sudden death in young athletes. Hum Pathol. 1983; 14:705-9.

11. James TN, Froggatt P, Marshall TK. Sudden death in young athletes. Ann Intern Med. 1967; 67:1013-21.

12. Topaz O, Edwards JE. Pathologic features of sudden death in children, adolescents, and young adults. Chest. 1985; 87:476-82.

13. Maron BJ, Poliac LC, Kaplan JA, Mueller FO. Blunt impact to the chest leading to sudden death from cardiac arrest during sports activities. N Engl J Med. 1995; 33:337-42.

14. Maron BJ, Strasburger JF, Kugler JD, Bell BM, Brodkey FD, Poliac LC. Survival following blunt chest impact-induced cardiac arrest during sports activities in young athletes. Am J Cardiol. 1997; 79:840-1.

15. Estes NA 3d. Sudden death in young athletes [Editorial]. N Engl J Med. 1995; 333:380-1.

16. Maron BJ, Stead D, Aeppli D. Prevalence of sudden cardiac death during competitive sports activities in interscholastic athletes in Minnesota [Abstract]. Circulation. 1996; 94:1-388.

17. Siscovick DS, Weiss NS, Fletcher R, Lasky T. The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med. 1984; 311:874-7.

18. Thompson PD, Funk EJ, Carleton RA, Sturner WQ. Incidence of death during jogging in Rhode Island from 1975 through 1980. JAMA. 1982; 247:2535-8.

19. Maron BJ, Poliac LC, Roberts WO. Risk for sudden cardiac death associated with marathon running. J Am Coll Cardiol. 1996; 28:428-31.

20. Huston TP, Puffer JC, Rodney WM. The athletic heart syndrome. N Engl J Med. 1985; 313:24-32.

21. Maron BJ. Structural features of the athlete heart as defined by echocardiography. J Am Coll Cardiol. 1986; 7:190-203.

22. Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med. 1991; 324:295-301.

23. Pelliccia A, Maron BJ, Culasso F, Spataro A, Caselli G. Athlete's heart in women. Echocardiographic characterization of highly trained elite female athletes. JAMA. 1996; 276:211-5.

24. Zeppilli P, Santini C, Palmieri V, Vannicelli R, Giordano RP, Frustaci A. Role of myocarditis in athletes with minor arrhythmias and/or echocardiographic abnormalities. Chest. 1994; 106:373-80.

25. Aretz HT, Billingham ME, Edwards WD, Factor SM, Falon JT, Fenoglio JJ Jr, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol. 1986; 1:3-14.

26. Phillips M, Robinowitz M, Higgins JR, Boran KJ, Reed T, Virmani R. Sudden cardiac death in Air Force recruits. A 20-year review. JAMA. 1986; 256:2696-9.

27. Lambert EC, Menon VA, Wagner HR, Vlad P. Sudden unexpected death from cardiovascular disease in children. A cooperative international study. Am J Cardiol. 1974; 34:89-96.

28. Isner JM, Estes M 3d, Thompson PD, Costanzo-Nordin MR, Subramanian R, Miller G, et al. Acute cardiac events temporally related to cocaine abuse. N Engl J Med. 1986; 325:1438-43.

29. Kloner RA, Hale S, Alker K, Rezkalla S. The effects of acute and chronic cocaine use on the heart. Circulation. 1992; 85:407-19.

30. Virmani R, Robinowitz M, Smialek JE, Smyth DF. Cardiovascular effects of cocaine: an autopsy study of 40 patients. Am Heart J. 1988; 115:1068-76.

31. Corrado D, Basso C, Poletti A, Angelini A, Valente M, Thiene G. Sudden death in the young. Is acute coronary thrombosis the major precipitating factor? Circulation. 1994; 90:2315-23.

32. Maron BJ, Bonow RO, Cannon RO 3d, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med. 1987; 316:780-9.

33. Maron BJ, Bonow RO, Cannon RO 3d, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med. 1987; 316:844-52.

34. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis. 1985; 28:1-83.

35. Maron BJ. Hypertrophic cardiomyopathy. Lancet. 1997; 350:127-33.

36. Schwartz K, Carrier L, Guicheney P, Komajda M. Molecular basis of familial cardiomyopathies. Circulation. 1995; 91:532-40.

37. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997; 336:775-85.

38. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation. 1995; 91:532-40.

39. Niimura H, Bachinski LL, Sangwatoraj S, Watkins H, Chudley AE, McKenna W, et al. Human cardiac myosin binding protein C mutations cause late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998; 338:1248-57.

40. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild D. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995; 92:785-9.

41. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation. 1982; 65:1388-94.

42. Maron BJ, Cecchi F, McKenna WJ. Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. Br Heart J. 1994; 72(6 Suppl):S13-8.

43. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol. 1981; 48:252-7.

44. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley CM, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J. 1981; 46:168-72.

45. Spirito P, Rapezzi C, Autore C, Bruzzi P, Bellone P, Ortolani P, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation. 1994; 90:2743-7.

46. Lewis JF, Spirito P, Pelliccia A, Maron BJ. Usefullness of Doppler echocardiographic assessment of diastolic filling in distinguishing "athlete's heart" from hypertrophic cardiomyopathy. Br Heart J. 1992; 68:296-300.

47. Cheitlin MD, De Castro CM, McAllister HA. Sudden death as a complication of anomalous left coronary origin from the anterior sinus of Valsalva, a not-so-minor congenital anomaly. Circulation. 1974; 50:780-7.

48. Roberts WC, Kragel AH. Anomalous origin of either the right or left main coronary artery from the aorta without coursing of the anomalistically arising artery between aorta and pulmonary trunk. Am J Cardiol. 1988; 62:1263-7.

49. Maron BJ, Leon MB, Swain JA, Cannon RO 3d, Pelliccia A. Prospective identification by two-dimensional echocardiography of anomalous origin of the left main coronary artery from the right sinus of Valsalva. Am J Cardiol. 1991; 68:140-2.

50. Jureidini SB, Eaton C, Williams J, Nouri S, Appleton RS. Transthoracic two-dimensional and color flow echocardiographic diagnosis of aberrant left coronary artery. Am Heart J. 1994; 127:438-40.

51. Gaither NS, Rogan KM, Stajduhar K, Banks AK, Hull RW, Whitsitt T, et al. Anomalous origin and course of coronary arteries in adults: identification and improved imaging utilizing transesophageal echocardiography. Am Heart J. 1991; 122:69-75.

52. Daliento L, Turrini P, Nava A, Rizzoli G, Angelini A, Buja G, et al. Arrhythmogenic right ventricular cardiomyopathy in young versus adult patients: similarities and differences. J Am Coll Cardiol. 1995; 25:655-64.

53. Pelliccia A, Maron BJ. Preparticipation cardiovascular evaluation of the competitive athlete: perspectives from the 30-year Italian experience [Editorial]. Am J Cardiol. 1995; 75:827-9.

54. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med. 1989; 320:749-55.

55. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol. 1995; 26:1529-36.

56. Maron BJ, Kogan J, Proschan MA, Hecht GM, Roberts WC. Circadian variability in the occurrence of sudden cardiac death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1994; 23:1405-9.

57. Maron BJ, Mitchell JH. 26th Bethesda Conference. Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. J Am Coll Cardiol. 1994; 24:845-99.

58. Maron BJ, Poliac LC, Mathenge R. Hypertrophic cardiomyopathy as an important cause of sudden cardiac death on the athletic field in African-American athletes [Abstract]. J Am Coll Cardiol. 1997; 29(Suppl A):462A.

59. Kerber RE, Becker LB, Bourland JD, Cummins RO, Hallstrom AP, Michos MB, et al. Automatic external defibrillators for public access defibrillation: recommendations for specifying and reporting arrhythmia analysis algorithm performance, incorporating new waveforms, and enhancing safety. A statement for health professionals from the American Heart Association Task Force on Automatic External Defibrillation, Subcommittee on AED Safety and Efficacy. Circulation. 1997; 95:1677-82.

60. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation. 1995; 91:1596-601.

61. Maron BJ, Moller JH, Seidman CE, Vincent GM, Dietz HC, Moss AJ, et al. Impact of laboratory molecular diagnosis on genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long QT syndrome and Marfan syndrome. Circulation. [In press].

62. Maron BJ, Isner JM, McKenna WJ. Hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases, and mitral valve prolapse. Task Force 3. In: 26th Bethesda Conference. Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. J Am Coll Cardiol. 1994; 24:880-5.

63. Maron BJ, Thompson PD, Puffer JC, McGrew CA, Strong WB, Douglas PS, et al. Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association. Circulation. 1996; 94:850-6.

64. Maron BJ, Bodison S, Wesley YE, Tucker E, Green KJ. Results of screening a large group of intercollegiate competitive athletes for cardiovascular disease. J Am Coll Cardiol. 1987; 10:1214-22.

65. Lewis JF, Maron BJ, Diggs JA, Spencer JE, Mehrotra PP, Curry CL. Preparticipation echocardiographic screening for cardiovascular disease in a large, predominantly black population of collegiate athletes. Am J Cardiol. 1989; 64:1029-33.

66. Fuller CM, McNulty CM, Spring DA, Arger KM, Bruce SS, Chryssos BE, et al. Prospective screening of 5,615 high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc. 1997; 29:1131-8.

67. Glover DW, Maron BJ. Profile of preparticipation cardiovascular screening for competitive athletes in United States high schools. JAMA. 1998; 279:1817-9.

68. Corrado D, Basso C, Thiene G. Preparticipation cardiovascular screening and sudden death in young competitive athletes. A prospective clinical and pathological study [Abstract]. Circulation. 1997; 96(Suppl I):I-152.

69. Knapp v. Northwestern University, 101F. 3d 473 (7th Cir 22 November 1996). U.S. Court of Appeals; No. 96-3450.

70. Maron BJ, Poliac JC, Kyle SB. Clinical profile of commotio cordis: an under-appreciated cause of sudden cardiac death in the young during sporting activities [Abstract]. Circulation. 1997; 96(Suppl 10):I-755.

71. Schlomka G, Hinrichs A. Experimentelle Untersuchungen uber den Einfluss Stumpfer Brustkortverletrungen auf dus Elektrokardiogram. Zeitschrift fur die Gesamte experimentelle Medizin einschliesslich experimentelle Chirurgie (Berlin). 1932; 81:43-61.

72. Link MS, Wang PJ, Pandian NG, Udelson JE, Lee MY, Vecchiotti MA, et al. An experimental model of commotio cordis: sudden death due to low energy chest wall impact. N Engl J Med. [In press].

73. Maron BJ. Athlete's heart and sudden cardiac death. In: Topol EJ, ed. Comprehensive Cardiovascular Medicine. Philadelphia: Lippincott-Raven; 1998; 1081-95.


This article has been cited by other articles:


Home page
CirculationHome page
R. J. Myerburg and V. L. Vetter
Electrocardiograms Should Be Included in Preparticipation Screening of Athletes
Circulation, November 27, 2007; 116(22): 2616 - 2626.
[Full Text] [PDF]


Home page
CirculationHome page
B. J. Maron, P. D. Thompson, M. J. Ackerman, G. Balady, S. Berger, D. Cohen, R. Dimeff, P. S. Douglas, D. W. Glover, A. M. Hutter Jr, et al.
Recommendations and Considerations Related to Preparticipation Screening for Cardiovascular Abnormalities in Competitive Athletes: 2007 Update: A Scientific Statement From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation
Circulation, March 27, 2007; 115(12): 1643 - 1655.
[Full Text] [PDF]


Home page
CirculationHome page
B. J. Maron and A. Pelliccia
The Heart of Trained Athletes: Cardiac Remodeling and the Risks of Sports, Including Sudden Death
Circulation, October 10, 2006; 114(15): 1633 - 1644.
[Full Text] [PDF]


Home page
JAMAHome page
T. E. Paterick, T. J. Paterick, G. F. Fletcher, and B. J. Maron
Medical and Legal Issues in the Cardiovascular Evaluation of Competitive Athletes
JAMA, December 21, 2005; 294(23): 3011 - 3018.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
R. E. Eckart, S. L. Scoville, C. L. Campbell, E. A. Shry, K. C. Stajduhar, R. N. Potter, L. A. Pearse, and R. Virmani
Sudden Death in Young Adults: A 25-Year Review of Autopsies in Military Recruits
Ann Intern Med, December 7, 2004; 141(11): 829 - 834.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. J. Maron, B. R. Chaitman, M. J. Ackerman, A. Bayes de Luna, D. Corrado, J. E. Crosson, B. J. Deal, D. J. Driscoll, N.A. M. Estes III, C. G. S. Araujo, et al.
Recommendations for Physical Activity and Recreational Sports Participation for Young Patients With Genetic Cardiovascular Diseases
Circulation, June 8, 2004; 109(22): 2807 - 2816.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
B. J. Maron
Sudden Death in Young Athletes
N. Engl. J. Med., September 11, 2003; 349(11): 1064 - 1075.
[Full Text] [PDF]


Home page
JAMAHome page
B. J. Maron, L. C. Poliac, A. B. Ashare, and W. A. Hall
Sudden Death Due to Neck Blows Among Amateur Hockey Players
JAMA, August 6, 2003; 290(5): 599 - 601.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. J. Maron, K. P. Carney, H. M. Lever, J. F. Lewis, I. Barac, S. A. Casey, and M. V. Sherrid
Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy
J. Am. Coll. Cardiol., March 19, 2003; 41(6): 974 - 980.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. A. Epstein, D. J. Rader, and M. S. Parmacek
Perspective: Cardiovascular Disease in the Postgenomic Era--Lessons Learned and Challenges Ahead
Endocrinology, June 1, 2002; 143(6): 2045 - 2050.
[Full Text] [PDF]


Home page
JAMAHome page
B. J. Maron, T. E. Gohman, S. B. Kyle, N. A. M. Estes III, and M. S. Link
Clinical Profile and Spectrum of Commotio Cordis
JAMA, March 6, 2002; 287(9): 1142 - 1146.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al.
Task Force on Sudden Cardiac Death of the European Society of Cardiology
Eur. Heart J., August 2, 2001; 22(16): 1374 - 1450.
[PDF]


Home page
CirculationHome page
B. J. Maron, C. G. S. Araujo, P. D. Thompson, G. F. Fletcher, A. B. de Luna, J. L. Fleg, A. Pelliccia, G. J. Balady, F. Furlanello, S. P. Van Camp, et al.
Recommendations for Preparticipation Screening and the Assessment of Cardiovascular Disease in Masters Athletes : An Advisory for Healthcare Professionals From the Working Groups of the World Heart Federation, the International Federation of Sports Medicine, and the American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention
Circulation, January 16, 2001; 103(2): 327 - 334.
[Full Text] [PDF]


Home page
JAMAHome page
G. C. Pfister, J. C. Puffer, and B. J. Maron
Preparticipation Cardiovascular Screening for US Collegiate Student-Athletes
JAMA, March 22, 2000; 283(12): 1597 - 1599.
[Abstract] [Full Text] [PDF]


box Article
 arrow  Table of Contents                
space
 arrow  Abstract of this article Free
space
 arrow  Figures/Tables List
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Maron, B. J.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online